Press Release Forum [] Forum Index

Press Release Forum []
Free Press Release Distribution

A site of EPR Network

 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 

Real Time Press Release Distribution is here. Try it out, it's free!


AnaSpec Introduces Beta- Secretase Enzyme & Assay

Post new topic   Reply to topic    Press Release Forum [] Forum Index -> Biotech Press Releases
View previous topic :: View next topic  
Author Message

Joined: 15 Aug 2006
Posts: 238
Location: 34801 Campus Drive, Fremont, CA 94555

PostPosted: Fri Oct 16, 2009 12:34 pm    Post subject: AnaSpec Introduces Beta- Secretase Enzyme & Assay Reply with quote

Fremont, CA – October 16, 2009

As one of the world’s largest providers of beta-amyloid peptides and Alzheimer’s related research products, AnaSpec has announced its latest offering – the human recombinant beta-secretase enzyme.

b- secretase (BACE1) is a key protease involved in the production of beta-amyloid peptides found in extracellular amyloid plaques of patients with Alzheimer’s disease (AD).1 This enzyme has been implicated as an important target for anti-amyloid therapy of AD.2

The recombinant human BACE1 contains the catalytic domain and a C-terminal His tag. The protein was expressed as inclusion bodies in E. coli. It was refolded and purified using ion exchange and IMAC chromatography.3 Enzyme activity can been measured in fluorescence resonance energy transfer (FRET) substrate based assays (e.g. SensoLyte® 520 beta-Secretase Assay Kit, cat# 71144). 100 ng of b-secretase is sufficient for this FRET-based assay.

AnaSpec’s SensoLyte™ 520 b-Secretase Assay Kit (cat# 71144) is the industry’s only long wavelength assay kit in the green range. This kit is a fluorimetric assay kit and is sensitive, robust and easy-to-use. It employs a FRET peptide (mentioned above), facilitating high throughput screening of beta-secretase targeting drug candidates. The sequence of this FRET peptide is derived from the beta-secretase cleavage site of beta-amyloid precursor protein (APP) with Swedish mutation. This mutation enhances the susceptibility of APP to beta-secretase and results in an early onset of AD.

1. Willem, M. et al. Semin Cell Dev Biol. 20,175 (2009).
2. Ghosh, K. et al. Neurotherapeutics 5, 399 (2008).
3. Tomasselli, G. et al. Protein & Peptide Letters. 15,131 (2008).

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

For more information visit

Ping Yang
Marketing Speialist
34801 Campus Drive
Fremont, CA 94555
1-800-452-5530 (Toll free)
1-510-791-9560 (Tel)
1-510-791-9572 (Fax)
Back to top
View user's profile Send private message Send e-mail Visit poster's website
Display posts from previous:   
Post new topic   Reply to topic    Press Release Forum [] Forum Index -> Biotech Press Releases All times are GMT - 4 Hours
Page 1 of 1

Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum

Submit Press Release (Free)Submit Press Release


Editor's pick: